The estimated Net Worth of Stephen A Sherwin is at least $9.47 Millón dollars as of 29 May 2024. Stephen Sherwin owns over 40,000 units of Neurocrine Biosciences stock worth over $5,041,491 and over the last 21 years he sold NBIX stock worth over $3,892,756. In addition, he makes $534,600 as Independent Director at Neurocrine Biosciences.
Stephen has made over 22 trades of the Neurocrine Biosciences stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 40,000 units of NBIX stock worth $1,787,200 on 29 May 2024.
The largest trade he's ever made was exercising 40,000 units of Neurocrine Biosciences stock on 29 May 2024 worth over $1,787,200. On average, Stephen trades about 2,481 units every 44 days since 2003. As of 29 May 2024 he still owns at least 41,504 units of Neurocrine Biosciences stock.
You can see the complete history of Stephen Sherwin stock trades at the bottom of the page.
Dr. Stephen A. Sherwin M.D. serves as Independent Director of the Company. Dr. Sherwin has served on the Board of Directors since April 1999. Dr. Sherwin currently divides his time between advisory work in the life science industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital. Dr. Sherwin currently serves on the Board of Directors of Aduro Biotech, Biogen and Neon Therapeutics. He is a Venture Partner with Third Rock Ventures and a member of the Scientific Steering Committee of the Parker Institute for Cancer Immunotherapy. Previously Dr. Sherwin was chairman and chief executive officer of Cell Genesys, a cancer immunotherapy company, from 1990 until the company’s merger in 2009 with BioSante Pharmaceuticals (now ANI Pharmaceuticals). He was also a co-founder and chairman of Abgenix, an antibody company which was acquired by Amgen in 2006, and co-founder and chairman of Ceregene, a gene therapy company which was acquired by Sangamo Biosciences in 2013. From 1983 to 1990, Dr. Sherwin held various positions in clinical research at Genentech, most recently that of Vice President. Prior to 1983, he was on the staff of the National Cancer Institute. In addition, Dr. Sherwin previously served on the board of directors of the Biotechnology Industry Organization from 2001 to 2014 and as its chairman from 2009 to 2011, and was a member of the President’s Council of Advisors in Science and Technology (PCAST) Working Group on Drug Development from 2011 to 2013. Dr. Sherwin holds a B.A. in biology summa cum laude from Yale University and an M.D. from Harvard Medical School, is board-certified in internal medicine and medical oncology, and is a fellow of the American College of Physicians.
As the Independent Director of Neurocrine Biosciences, the total compensation of Stephen Sherwin at Neurocrine Biosciences is $534,600. There are 14 executives at Neurocrine Biosciences getting paid more, with Kevin Gorman having the highest compensation of $9,450,830.
Stephen's mailing address filed with the SEC is 12780, El Camino Real, San Diego, San Diego County, California, 92014, United States.
Over the last 22 years, insiders at Neurocrine Biosciences have traded over $159,913,426 worth of Neurocrine Biosciences stock and bought 103,400 units worth $589,660 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... y Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of $1,567,813. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth $2,090,333.
neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders
Neurocrine Biosciences executives and other stock owners filed with the SEC include: